Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. Abstract Text:

PURPOSE: One third of women with advanced human epidermal growth factor receptor 2 (HER-2)-positive breast cancer develop brain metastases; a subset progress in the CNS despite standard approaches. Medical therapies for refractory brain metastases are neither well-studied nor established. We evaluated the safety and efficacy of lapatinib, an oral inhibitor of epidermal growth factor receptor (EGFR) and HER-2, in patients with HER-2-positive brain metastases. PATIENTS AND METHODS: Patients had HER-2-positive breast cancer, progressive brain metastases, prior trastuzumab treatment, and at least one measurable metastatic brain lesion. Patients received lapatinib 750 mg orally twice a day. Tumor response was assessed by magnetic resonance imaging every 8 weeks. The primary end point was objective response (complete response [CR] plus partial response [PR]) in the CNS by Response Evaluation Criteria in Solid Tumors (RECIST). Secondary end points included objective response in non-CNS sites, time to progression, overall survival, and toxicity. RESULTS: Thirty-nine patients were enrolled. All patients had developed brain metastases while receiving trastuzumab; 37 had progressed after prior radiation. One patient achieved a PR in the brain by RECIST (objective response rate 2.6%, 95% conditional CI, 0.21% to 26%). Seven patients (18%) were progression free in both CNS and non-CNS sites at 16 weeks. Exploratory analyses identified additional patients with some degree of volumetric reduction in brain tumor burden. The most common adverse events (AEs) were diarrhea (grade 3, 21%) and fatigue (grade 3, 15%). CONCLUSION: The study did not meet the predefined criteria for antitumor activity in highly refractory patients with HER-2-positive brain metastases. Because of the volumetric changes observed in our exploratory analysis, further studies are underway utilizing volumetric changes as a primary end point.

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Journal of clinical oncology : official journal of

VOLUME: 26

Page Numbers: 1993-9

Journal Abbreviation: J. Clin. Oncol.

ISSN: 1527-7755

DAY: 20

MONTH: Apr

YEAR: 2008

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8309333

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.

AFFILIATION: Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA.

Country: United States

AGENCY: United States NIBIB

GRANT: R01EB000219

ACRONYM: EB

MEDLINETA: J Clin Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer Related Publications

• A framework for interactive examination of automatic segmented tumors in a virtual environment.
• A simple approach to quality assurance in a complex ambulatory care setting.
• Advances in adjuvant endocrine therapy for postmenopausal women.
• Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI.
• Auditory cortex mapmaking: principles, projections, and plasticity.
• Branched projections in the auditory thalamocortical and corticocortical systems.
• Commoner skin diseases of the external genitalia.
• Concurrent tonotopic processing streams in auditory cortex.
• Connections of cat auditory cortex: I. Thalamocortical system.
• Connections of cat auditory cortex: II. Commissural system.
• Connections of cat auditory cortex: III. Corticocortical system.
• Cutaneous leishmaniasis; report of a case and summary of the newer concepts.
• Drospirenone/ethinyl estradiol.
• Elastic fibers in unusual dermatoses.
• Follow-up care of patients with breast cancer.
• Herpes zoster and malignancy.
• Heterogeneity of breast cancer and implications of adjuvant chemotherapy.
• How does infiltration behavior modify the composition of ambient PM2.5 in indoor spaces? An analysis of RIOPA data.
• Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors.
• Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer.
• Optimizing endocrine therapy for estrogen receptor-positive breast cancer: treating the right patients for the right length of time.
• Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.
• Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.
• Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions.
• Racial Differences in Clinical Outcomes From Metastatic Breast Cancer: A Pooled Analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.
• Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study.
• Sarcoidosis mimicking metastatic breast cancer.
• The pharmacologic management of premenstrual dysphoric disorder.
• Uterine inversion associated with bicornuate uterus.
• Vascular compliance in the cardiometabolic syndrome.